Medicare and Medicaid Services Not to Go Forward With Part B Payment Proposal
Published : 2016-12-17 - Updated : 2020-04-11
Author : American College of Rheumatology - Contact: rheumatology.org
🛈 Synopsis : Medicare beneficiaries living with rheumatic diseases are able to continue receiving therapies to manage their chronic conditions and avoid pain and disability. More than 52.5 million people - one in five Americans - live with rheumatic diseases, according to the Centers for Disease Control and Prevention (CDC). For seniors living with painful and debilitating diseases like rheumatoid arthritis, lupus, spondyloarthritis, psoriatic arthritis, safe access to biologic therapies is a necessity.
The American College of Rheumatology (ACR) applauds the decision from the Centers for Medicare & Medicaid Services (CMS) not to go forward with the agency's controversial Part B payment proposal, noting that the hard-fought outcome is good news for rheumatology patients who rely on Medicare Part B to access life-saving biologic therapies.
"We thank CMS for listening to the rheumatology community's concerns about the negative and disproportionate impact this proposal would have on our Medicare patients living with rheumatic diseases by not moving forward with this Part B Demonstration Project," said Dr. Sharad Lakhanpal, MBBS, MD, President of the ACR.
"For older Americans living with painful and debilitating diseases like rheumatoid arthritis, lupus, spondyloarthritis, and psoriatic arthritis, safe access to biologic therapies is not an option but a necessity - which is why the ACR has been vocal in expressing our concerns about the unintended consequences of this proposal and its flawed cost-savings premise. This positive outcome will help ensure Medicare beneficiaries living with rheumatic diseases are able to continue receiving the therapies they need to manage their chronic conditions and avoid pain and disability."
From the time it was proposed in March 2016, the ACR has voiced strong opposition to the proposed rule.
In detailed comments submitted to CMS earlier this year, the ACR expressed concerns about the lack of less expensive yet clinically equivalent biologic therapy options in the marketplace for Medicare patients living with rheumatic diseases, as well as the safety and health dangers posed by switching from a biologic therapy that works well for the patient.
The ACR has also noted that many rheumatologists - particularly small or rural practices that lack the ability to negotiate bulk discounts with pharmaceutical companies - have already been forced to stop administering biologic therapies to Medicare patients because the current Part B payment structure does not cover the costs of obtaining and providing these complex therapies in the outpatient setting.
If the additional payment cuts proposed by CMS in the Part B Demonstration Project were to go through, the ACR warned that many rheumatology patients would be forced into less safe or more expensive settings to receive needed therapies, if these patients were able to receive them at all.
More than 52.5 million people - one in five Americans - live with rheumatic diseases, according to the Centers for Disease Control and Prevention (CDC).
Rheumatic diseases are the nation's leading cause of disability, contributing more than $128 billion in costs to the U.S. healthcare system each year.
Source/Reference: American College of Rheumatology (rheumatology.org). Disabled World makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.
Related U.S. Medicare Documents
- 1: Danger of Copayment on Medicare Home Health Services : New Commonwealth fund study findings underscore danger of a copayment on medicare home health services.
- 2: Key Drivers of Health Care Costs : A policy paper that identifies and analyzes the key drivers of health care costs was released today by the American College of Physicians.
- 3: Lower Out of Pocket Insulin Costs for U.S. Medicare Seniors : Across America, 88 Part D Sponsors applied to the Part D Senior Savings Model to offer enhanced plans with a maximum $35 copay for a broad set of insulins beginning in 2021.
- 4: Medicare and Medicaid Services Not to Go Forward With Part B Payment Proposal : Medicare beneficiaries living with rheumatic diseases are able to continue receiving therapies to manage their chronic conditions and avoid pain and disability.
- 5: U.S. Medicare and Telehealth Services During COVID-19 Pandemic : Due to COVID-19 Medicare temporarily expands coverage of telehealth services, including evaluation and management visits, mental health counseling and preventive health screenings.
You're reading Disabled World. Be sure to check out our homepage for further informative disability news, reviews, exclusive stories and how-tos. You can also follow Disabled World on social media sites such as Twitter, Facebook, and LinkedIn.
Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.
Journal: Disabled World. Language: English (U.S.). Author: American College of Rheumatology. Electronic Publication Date: 2016-12-17 - Revised: 2020-04-11. Title: Medicare and Medicaid Services Not to Go Forward With Part B Payment Proposal, Source: <a href=https://www.disabled-world.com/medical/healthcare/us-medicare/acr.php>Medicare and Medicaid Services Not to Go Forward With Part B Payment Proposal</a>. Retrieved 2021-04-12, from https://www.disabled-world.com/medical/healthcare/us-medicare/acr.php - Reference: DW#281-12563.